Exceptional Response to Cabozantinib in a Patient With Multiply Relapsed Wilms Tumor.
作者信息
Anderson Bailey, Jasty-Rao Rama, Wu Yi-Mi, Paul Trisha, Robinson Dan, Mody Rajen J
机构信息
University of Michigan, Ann Arbor, MI.
出版信息
JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00021. Epub 2018 Jul 10.
Abstract
摘要
相似文献
1
Exceptional Response to Cabozantinib in a Patient With Multiply Relapsed Wilms Tumor.卡博替尼对一名多次复发的肾母细胞瘤患者有显著疗效。
JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00021. Epub 2018 Jul 10.
2
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.长春新碱、伊立替康、替莫唑胺和贝伐珠单抗治疗多发性复发性肾母细胞瘤。
Pediatr Blood Cancer. 2014 Apr;61(4):756-9. doi: 10.1002/pbc.24785. Epub 2013 Sep 21.
3
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.一项卡博替尼治疗儿童和青少年复发性或难治性实体瘤（包括 CNS 肿瘤）的 1 期研究：来自儿童肿瘤学组的 ADVL1211 试验报告。
Pediatr Blood Cancer. 2018 Aug;65(8):e27077. doi: 10.1002/pbc.27077. Epub 2018 Apr 25.
4
Combined computed tomography-guided radiofrequency ablation and brachytherapy in a child with multiple recurrences of Wilms' tumor.计算机断层扫描引导下射频消融与近距离放射治疗联合应用于一名多次复发的肾母细胞瘤患儿。
J Pediatr Hematol Oncol. 2005 Jul;27(7):377-9. doi: 10.1097/01.mph.0000173846.87539.a9.
5
[A long-term follow-up report of pediatric relapsed Wilms tumor after retreatment].[小儿复发性肾母细胞瘤再治疗后的长期随访报告]
Zhonghua Er Ke Za Zhi. 2017 Oct 2;55(10):743-747. doi: 10.3760/cma.j.issn.0578-1310.2017.10.006.
6
Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).复发性肾母细胞瘤（WT）患者的治疗：拓扑替康的应用经验。国际小儿肿瘤学会肾肿瘤研究组（RTSG）的报告
Pediatr Blood Cancer. 2015 Apr;62(4):598-602. doi: 10.1002/pbc.25357. Epub 2014 Dec 29.
7
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.异环磷酰胺、卡铂和依托泊苷用于高危复发性肾母细胞瘤患儿：儿童癌症研究组报告
Ann Oncol. 2002 Mar;13(3):460-9. doi: 10.1093/annonc/mdf028.
8
High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes.大剂量化疗及自体造血干细胞挽救治疗复发难治性肾母细胞瘤：重新评估疗效。
Pediatr Hematol Oncol. 2018 Aug-Sep;35(5-6):316-321. doi: 10.1080/08880018.2018.1532478. Epub 2019 Jan 25.
9
The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary metastases: a report from the National Wilms' Tumor Study.手术切除在复发性伴有肺转移的肾母细胞瘤患者治疗中的作用：来自国家肾母细胞瘤研究的报告
J Pediatr Surg. 1991 Jun;26(6):728-33. doi: 10.1016/0022-3468(91)90021-k.
10
Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.伊立替康用于小儿复发性肾母细胞瘤：国际小儿肿瘤学会（SIOP）的经验及文献综述——SIOP肾肿瘤研究组报告
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26849. Epub 2017 Oct 27.
引用本文的文献
1
Advances in the clinical management of high-risk Wilms tumors.高危 Wilms 肿瘤的临床管理进展。
Pediatr Blood Cancer. 2023 May;70 Suppl 2(Suppl 2):e30342. doi: 10.1002/pbc.30342.
2
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors.追求精准：用于治疗儿童实体瘤的受体酪氨酸激酶抑制剂
Cancers (Basel). 2021 Jul 14;13(14):3531. doi: 10.3390/cancers13143531.
3
Use of Antiangiogenic Therapies in Pediatric Solid Tumors.抗血管生成疗法在儿童实体瘤中的应用。
Cancers (Basel). 2021 Jan 12;13(2):253. doi: 10.3390/cancers13020253.
本文引用的文献
1
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.卡博替尼对比依维莫司、纳武利尤单抗、阿昔替尼、索拉非尼及最佳支持治疗：晚期肾细胞癌二线治疗中无进展生存期和总生存期的网状Meta分析
PLoS One. 2017 Sep 8;12(9):e0184423. doi: 10.1371/journal.pone.0184423. eCollection 2017.
2
Cabozantinib for the treatment of kidney cancer.卡博替尼用于治疗肾癌。
Expert Rev Anticancer Ther. 2017 Jul;17(7):577-584. doi: 10.1080/14737140.2017.1344553.
3
Wilms tumor: "State-of-the-art" update, 2016.肾母细胞瘤：2016年“最新进展”更新
Semin Pediatr Surg. 2016 Oct;25(5):250-256. doi: 10.1053/j.sempedsurg.2016.09.003. Epub 2016 Sep 4.
4
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.罕见肿瘤的综合基因组与实验性治疗方法的案例研究：小儿低分化癌中脆弱性的鉴定
Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0.
5
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.卡博替尼的临床药代动力学与药效学
Clin Pharmacokinet. 2017 May;56(5):477-491. doi: 10.1007/s40262-016-0461-9.
6
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.卡博替尼对比依维莫司治疗晚期肾细胞癌（METEOR）：一项随机、开放标签、III 期临床试验的最终结果。
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
7
Strategically targeting MYC in cancer.在癌症中对MYC进行战略性靶向治疗。
F1000Res. 2016 Mar 29;5. doi: 10.12688/f1000research.7879.1. eCollection 2016.
8
Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.种系HOXB13基因p.Gly84Glu突变与癌症易感性：对25项流行病学研究中145257名参与者的汇总分析
Oncotarget. 2015 Dec 8;6(39):42312-21. doi: 10.18632/oncotarget.5994.
9
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.靶向MET和AXL可克服肾细胞癌对舒尼替尼治疗的耐药性。
Oncogene. 2016 May;35(21):2687-97. doi: 10.1038/onc.2015.343. Epub 2015 Sep 14.
10
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.青少年难治性或复发性癌症管理中的综合临床测序
JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080.
Zotero 插件